(Hong Kong, 13 May 2026) – Hong Kong Science and Technology Parks Corporation (HKSTP) extends its warmest congratulations to its park company, Metis TechBio (7666.HK), on its successful listing on the Hong Kong Stock Exchange (HKEX) today. The company is the world’s first publicly listed AI drug delivery company, with its innovative solutions set to reshape how therapeutics are delivered within the human body.
Mr Terry Wong, CEO of HKSTP, said, “We sincerely congratulate Metis TechBio on its successful listing. This marks not only a major milestone in the company’s development, but also an important achievement of Hong Kong’s innovation and technology (I&T) ecosystem. Leveraging its breakthrough AI technologies and innovative drug delivery platform, Metis TechBio has rapidly emerged in the global life and health tech arena, showcasing Hong Kong’s strength in research, talent and capital markets. We have been supporting tech firms at different stages of development, and we look forward to Metis TechBio’s continued innovation in Hong Kong, the Chinese Mainland and beyond, contributing to advancements in human health.”
Metis TechBio is an I&T company focused on AI-driven drug delivery and biopharmaceutical R&D. By integrating advanced AI with nanoscience, the company develops efficient, safe and precise therapeutic solutions. Through its self-developed platform, NanoForge — the world’s first AI-powered nanodelivery platform — Metis TechBio has built the world’s largest ionisable lipid library in the industry, comprising over 10 million structurally diverse lipids. The company has also developed the world’s only de novo lipid generation algorithms and lipid language models, and established the first end-to-end screening platform for lipids and lipid nanoparticles (LNP), alongside the world’s first multi-scale simulation platform for small molecule formulations empowered by AI+. Powered by NanoForge, Metis TechBio has been the first in the industry to achieve precise targeted delivery across eight key organs and tissues, including the liver, lungs, heart, muscles, tumour tissues, immune system, central nervous system and gastrointestinal tract. Its pipeline spans oncology, immunology, central nervous system and metabolic diseases.
As a park company at Hong Kong Science Park, Metis TechBio actively leverages the city’s vibrant I&T ecosystem to advance innovation in AI-powered nanodelivery and interdisciplinary research. The company has established partnerships with more than 30 pharmaceutical and biotechnology organisations globally, including leading pharmaceutical companies, innovative biotech firms and medical research institutions.
HKSTP has built a thriving I&T ecosystem, supporting 12 unicorns and bringing together approximately 2,500 technology companies from 26 countries and regions, with over 17,000 research professionals. We will continue to support park companies, accelerate the commercialisation of R&D outcomes, and work closely with industry partners to strengthen Hong Kong’s I&T advantages, reinforcing its position as a international I&T hub.
